CRISPR Therapeutics AG (CRSP) Financials
Key financial figures for CRISPR Therapeutics AG (Q2 2026).
CRISPR Therapeutics reports Q2 2026 net loss of $91.2 million as CASGEVY revenue reaccelerates to $76 million and collaboration revenue reaches $10.0 million. CASGEVY (Vertex-led, CRISPR Therapeutics 40% profit share) generated $76 million in total product revenue in Q2 2026, up 78% quarter-over-quarter and 151% year-over-year. CRISPR Therapeutics' own collaboration revenue was $10.0 million in Q2 2026, versus $0 in Q2 2025, its largest quarterly share to date. R&D expenses were $67.2 million, down 4% year-over-year; total operating expenses were $127.5 million, down 45% year-over-year from Q2 2025's $230.2 million. Net loss narrowed to $91.2 million ($(0.94) per share, basic and diluted) from $208.5 million ($(2.40) per share) in Q2 2025. Figures are for Q2 2026, as CRISPR Therapeutics AG reported them.
- Revenue
- $10M
- Net Income
- -$91M
- EPS
- $-0.94
- Total Assets
- $2.7B
- Operating Cash Flow
- -$83M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $10M | -$91M | -$0.94 | -1127.55% | -$194M |
| Q1 FY2026 | $1M | -$123M | -$1.28 | -8933.33% | -$109M |
| Q4 FY2025 | $864K | -$131M | -$1.37 | -17912.5% | -$93M |
| Q3 FY2025 | $889K | -$106M | -$1.17 | -14854.78% | -$85M |
| Q2 FY2025 | $892K | -$209M | -$2.40 | -14918.27% | -$114M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $4M | -$582M | -$6.47 | -16191.4% | -$346M |
| FY2024 | $35M | -$366M | -$4.34 | -1333.05% | -$145M |
| FY2023 | $370M | -$154M | -$1.94 | -60.15% | -$270M |
Frequently asked questions
What was CRISPR Therapeutics AG's revenue last quarter?
CRISPR Therapeutics AG reported revenue of $10.2 million for Q2 FY2026, up 1041.4% from the same period a year earlier.
Is CRISPR Therapeutics AG profitable?
Not in its most recent reported period. CRISPR Therapeutics AG reported a net loss of $91.2 million for Q2 FY2026, a net margin of -895.33% on revenue.
How has CRISPR Therapeutics AG's margin trended?
Operating margin was -1127.55% in Q2 FY2026, compared with -14918.27% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did CRISPR Therapeutics AG generate?
CRISPR Therapeutics AG generated free cash flow of -$193.5 million in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for CRISPR Therapeutics AG on SentiSense, with up to forty quarters and twenty fiscal years of history.